3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Status
Withdrawn
2
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
26
Prostatic Neoplasms
15
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasms
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Neurofibrosarcoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Cholangiocarcinoma
2
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT02947113
2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2
Withdrawn
NCT01936961
2017-06-27
I-CREST
Western Regional Medical Center
Phase NA
Withdrawn